Current treatment guidelines recommend considering adjuvant AI therapy for most postmenopausal women with early estrogen receptor (ER)-positive breast cancer and for high-risk premenopausal patients together with ovarian suppression [13, 14] AI therapy increases bone loss and the risk of fracture compared to estrogen receptor antagonists. The gene discussed is ESR1; the disease is breast carcinoma.